Viromed Medical AG's Cold Plasma Therapy Shows 100% Efficacy Against VAP

Viromed Medical AG has announced potent results from an in vitro study using cold plasma therapy to treat ventilator-associated pneumonia (VAP). Conducted by scientists at Hannover Medical School, the study revealed complete eradication of MRSA bacteria without damaging human lung cells.

The study's lead investigator, Prof. Dr. Hortense Slevogt, emphasized the method's effectiveness and safety, marking it as a pivotal alternative to traditional treatments. Viromed's CEO, Uwe Perbandt, highlighted the potential reduction in hospital mortality rates due to this innovative plasma technology.

With these findings, cold plasma is positioned as a promising advance in severe lung disease treatments, offering hope for global healthcare improvements. A publication and press conference are slated for June 2025 to detail these significant findings.